What question did this study set out to answer?

To update and validate the SMART2 algorithm for predicting recurrent atherosclerotic cardiovascular disease events in patients with established cardiovascular disease.

January 31, 2022European Heart JournalOpen Access

Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm

View Full Paper

Ask AI

Bookmark

Why the study?

Does the SMART2 risk score accurately predict recurrent ASCVD events in patients with established ASCVD?

Key Points

To update and validate the SMART2 algorithm for predicting recurrent atherosclerotic cardiovascular disease events in patients with established cardiovascular disease.
Updated the SMART2 risk prediction algorithm to evaluate residual cardiovascular risk in individuals with established atherosclerotic cardiovascular disease.
Assessed model validity across diverse European and non-European populations.
The updated SMART2 risk score successfully provides validated predictions of recurrent atherosclerotic cardiovascular events across international cohorts.
The tool delivers quantitative rather than qualitative estimates of residual cardiovascular risk to support personalized secondary prevention strategies.

Structured PICO

Does the SMART2 risk score accurately predict recurrent ASCVD events in patients with established ASCVD?

Population

Patients with established atherosclerotic cardiovascular disease (ASCVD) across European and non-European populations

Intervention

SMART2 risk score algorithm

Outcome

Prediction of recurrent ASCVD eventshard clinical

The SMART2 algorithm provides a validated, quantitative tool to personalize secondary prevention strategies by estimating residual risk of recurrent ASCVD events.

Implication

Supports residual risk estimation in secondary prevention; extends SMART2 validation in cohorts but leaves outcome impact open.

Abstract

The SMART2 risk score provides an updated, validated tool for the prediction of recurrent ASCVD events in patients with established ASCVD across European and non-European populations. The use of this tool could allow for a more personalized approach to secondary prevention based upon quantitative rather than qualitative estimates of residual risk.